What Is VIP?
Vasoactive Intestinal Peptide, usually shortened to VIP, is a naturally occurring 28-amino-acid peptide hormone. Despite the name, VIP is not limited to the intestines. It has broad activity across blood vessels, the immune system, the nervous system, the gut, the pancreas, circadian rhythm biology, and multiple organ systems.
VIP acts through VPAC1 and VPAC2 receptors, which are G protein-coupled receptors found throughout the body. When VIP binds to these receptors, it increases cyclic AMP signaling and activates downstream pathways involved in inflammation control, tissue repair, vascular relaxation, and neuroendocrine communication.
In functional medicine, VIP is most commonly discussed in the context of Chronic Inflammatory Response Syndrome, or CIRS, where low VIP levels are considered one contributor to persistent inflammation, chemical sensitivity, fatigue, brain fog, and multi-system dysfunction.
Neuroimmune Network Peptide
VIP sits at the intersection of the nervous, endocrine, immune, vascular, and gut systems. It does not simply suppress immune activity; it appears to help rebalance inflammatory signaling by reducing pro-inflammatory cytokines while supporting anti-inflammatory pathways.
VIP Benefits
VIP has the strongest human discussion around CIRS and pulmonary arterial hypertension research, while broader inflammatory, autoimmune, gut, and neuroprotective claims rely more heavily on mechanistic, animal, in vitro, or early clinical data.
CIRS & Mold Illness
VIP nasal spray is positioned as the final step in the Shoemaker CIRS protocol after exposure, MARCoNS, and other prerequisites have been addressed. Reported outcomes include improvements in symptoms, inflammatory markers, pulmonary pressure, hormones, and brain imaging findings.
Inflammation Balance
VIP is associated with reduced TNF-alpha, IL-6, IL-12, and Th17 signaling, while increasing IL-10 and supporting regulatory T-cell activity. This makes it relevant to chronic inflammatory and autoimmune research contexts.
Brain Fog & Cognition
CIRS reports frequently focus on improved brain fog and cognitive function. VIP also has neuroprotective and circadian rhythm roles that may influence sleep quality and cognitive performance.
Pulmonary & Vascular Effects
VIP relaxes smooth muscle in blood vessels and has been studied in pulmonary arterial hypertension, where inhaled VIP was associated with improved pulmonary pressure and physical capacity in a small open-label study.
Gut Barrier Support
VIP supports intestinal epithelial health, gut barrier integrity, water and ion balance, and immune signaling in the gut. These effects are relevant because gut barrier dysfunction is common in chronic inflammatory states.
Chemical Sensitivity
Low VIP levels are discussed in relation to multiple chemical sensitivity. Patient reports describe reduced environmental reactivity after VIP when the broader CIRS protocol context has been addressed.
What to Expect
VIP is not usually described as an acute “feel it immediately” peptide. Timelines are mostly derived from CIRS treatment communities and published Shoemaker protocol outcomes.
1–2 Weeks — Early Changes
Some users report improved energy, reduced brain fog, better sleep, or nasal irritation. Others report temporary worsening if prerequisites were not fully met.
2–4 Weeks — More Consistent Response
Fatigue reduction, cognitive improvement, and sleep-quality changes may become more noticeable for responders.
1–6 Months — Progressive Improvement
Clinical reports describe progressive changes in inflammatory markers, hormone normalization, chemical sensitivity, and brain imaging findings over longer treatment windows.
After Stop — Reassess Triggers
VIP levels and symptoms may drift if underlying inflammatory triggers remain. Some users require maintenance dosing, while others discontinue after a full course.
